Disclosed are implantable ocular drainage devices that include a reversible switch mechanism to control flow through the drainage device. The devices include a drainage tube and a reversible, bi-stable switch mechanism that includes first and second stationary magnets spaced apart from one another and a magnetic or ferromagnetic mobile element moveably disposed in a channel in the housing.

A shunt 200 for treating glaucoma in a patient during and/or after vitreoretinal surgery involving the use of a tamponading agent comprising a gas or oil bubble 50. The shunt includes a tubular body 12 having a proximal end 14 which is implantable in the vitreous cavity C of a patient and a distal end which is implantable in the subarachnoid space of the patient. The tubular body defines a lumen 18 extending between the distal and proximal ends. The shunt includes an occlusion body 32 defining a number of micro-passages 34 inflow communication with the lumen 18. The micro-passages are configured in terms of their size and number to provide sufficient surface tension and viscosity resistance in order to prevent the tamponading agent from passing through the micro-passages into the lumen, yet allow sufficient aqueous fluid from the vitreous cavity to travel along the micro-passages into the lumen 18 in order to regulate intraocular pressure.

Drainage device for draining a biological fluid from an eye to a tissue external to the eye, as well as methods of forming the drainage device and treating glaucoma using the drainage device, are disclosed. The drainage device is implantable at least in part within a tissue of the eye and includes a collapsible body portion defining a reservoir, and a conduit having a first end fluidly coupled with the reservoir and a second end insertable into the eye to facilitate a drainage of the biological fluid into the conduit. When collapsed, the body portion includes a deformation from a first planar state to a second nonplanar state, where the second nonplanar state may be a folded, deformed, bent, or crumpled state.

A device to treat an ocular condition having a rotary housing located within an outer housing rotationally fixed to a rotary spindle and rotationally movable relative to the outer housing; an elongate shaft projecting distally from the distal end region of the outer housing along a central longitudinal axis, at least a distal end region of the elongate shaft being sized for insertion into an eye. The elongate shaft includes an outer shaft and an inner cutting tube. Upon actuation of the device, the rotary housing rotates causing the rotary spindle and the inner cutting tube to rotate around the central longitudinal axis while simultaneously causing axial extension of the inner cutting tube distally along the central longitudinal axis to advance the distal cutting surface through a target tissue forming a tissue slug. Related devices, systems, and methods are provided.

Certain embodiments provide a cannula system with a retention mechanism comprising a cannula, a hub coupled to the cannula, wherein a distal end of the cannula is configured to be inserted into a body part up to the hub, and a retention mechanism configured to create resistance for retaining the cannula inside the body part in response to force exerted on the cannula for pulling the cannula out of the body part. The retention mechanism may include retention elements coupled to a bottom surface of the hub, and by rotating the hub in a first direction, the one or more retention elements that are parallel to a surface of the body part are configured to penetrate the body part. In other embodiments, the retention mechanism may include halfpipe elements that pivot on fulcrum points to hold or release the hub and cannula from the body part.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

A microsurgical device and methods of its use can be used for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. A dual-blade device can be used for cutting the trabecular meshwork (“TM”) in the eye. The device tip provides entry into the Schlemm's canal via its size (i.e., for example, 0.2-0.3 mm width) and configuration where a ramp elevates the TM away from the outer wall of the Schlemm's canal and guides the TM to first and second lateral elements for creating first and second incisions through the TM. The dimensions and configuration of the blade is such that an entire strip of TM is removed without leaving TM leaflets behind and without causing collateral damage to adjacent tissues.

A method of delivering a pharmaceutical composition to Schlemm’s canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm’s canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm’s canal as it erodes.

Systems, devices, and methods for treating a glaucomatous eye are provided. An amount of pulsed laser energy is delivered to the pars plana of the eye by a hand-holdable device which comprises a hand-holdable elongate member and a contact member disposed on an end of the elongate member. A contact surface of the contact member is placed in direct contact with the eye so that a reference edge of the contact member aligns with the limbus and a treatment axis defined by the elongate member is angularly offset from the optical axis of the eye. The amount of pulsed laser energy delivered is insufficient to effect therapeutic photocoagulation but is sufficient to increase uveoscleral outflow so as to maintain a reduction from pre-laser treatment intraocular pressure. Amounts of pulsed laser energy will be transmitted to a circumferential series of tissue regions of the eye.

A system for deploying an implant cut from a biological tissue into an eye of a patient including a delivery device and a nose cone assembly, a tubular shaft projecting from the distal end region of the nose cone and comprising a lumen. Related devices, systems, and methods are provided.